ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

ESMO25: On next-generation bispecifics, with Tadaaki Taniguc...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.

ESMO25: Immuno-therapies and translational research in oncol...

Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data

ESMO25: The changing landscape of rare oncology, with Jan Ki...

ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.

ESMO25: Following the science to a cure, with Nancy Ghattas

ESMO25: Acceleration, accessibility, and accuracy, with Barr...

At ESMO25, pharmaphorum spoke with Barry Vucsko, Senior VP of Strategic Development, Agency Services, for the EVERSANA Oncology Centre of Excellence.